He Jiankui’s Genetic Misadventure, Part 3: What Are the Major Ethical Issues?
By Jing-Bao Nie and Alexander T.M. Cheung,
The Hastings Center
| 01. 10. 2019
In their single-minded venture of “producing” (shengchan, in their own word) the world’s first gene-edited babies, He Jiankui and his associates have posed numerous and daunting ethical challenges to China and the world. They can be mapped or identified through these four categories:
- typical problems related to research ethics;
- broader political, socio-cultural, and transcultural issues;
- fundamental ethical questions on the use of gene editing in human reproduction itself; and
- even more fundamental matters on the moral goals of science and technology.
Different levels of ethical issues should be explored in an interconnected and interdisciplinary approach, but it is important to note that ethical soundness on one dimension does not mean moral justification on any other level or dimension.
Some prominent U.S. scientists, including George Church at Harvard, have offered a defence of He’s human experimentation on two grounds. First, genetically editing humans can be ethically justifiable. Second, the international community and Chinese society are bullying He for having not done “the paperwork right.” Church says he feels “an obligation to be balanced” about He’s case. Some international and Chinese...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...